Evotec acquires translational projects firm Bionamics
This article was originally published in Scrip
German drug discovery services firm Evotec has acquired Bionamics, a German asset management company, for an undisclosed amount. Bionamics is focused on translating academic innovations into useful projects for pharma and biotech companies. This is a good fit with Evotec's EVT Innovate, an initiative under which the company develops early stage projects until they are ready for licensing by pharma companies.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.